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patient privacy in research, it has significant limitations in
practice. Too often individuals give consent when they do
not fully understand the ramifications of what they have
agreed to-and this is particularly true for individuals who
are sick and vulnerable. CDT has written about the lim-
its of consent in protecting privacy in health care (Mc-
Graw 2009b), as well as on the Internet (CDT 2009). In
both articles, we caution against overreliance on the typ-
ical "notice and consent" framework for protecting privacy.
We have instead called for a comprehensive framework
of rules to protect information, so that consent cannot be
used as a shield for inappropriate uses and disclosures of
information.
The group harms discussed by Dr. Rothstein in his ar-
ticle would not be avoided by requiring individual con-
sent. Because of the limits of consent, too many individu-
als would still knowingly agree to participate in research
without a full appreciation of the potential adverse con-
sequences, either for themselves or for their peer groups.
We should not ask individuals to bear the burden of en-
suring the proper conduct of health information research.
Ultimately, we need a more effective paradigm for protect-
ing privacy, as well as individual autonomy and dignity,
while also advancing the conduct of research in the public
interest. 0
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Rothstein (2010) provides a carefully articulated critique of
our current approach to the privacy of research data, partic-
ularly that sourced from electronic medical records (EMRs).
The Common Rule and Health Insurance Portability and
Accountability Act (HIPAA) privacy protection "holes,"
and hence the underprotection of personal health data, trig-
gered by deidentification are well known. Rothstein's con-
tribution here is to expose the gross oversimplification of
the identification-deidentification binary. His article raises
further questions about deidentification as an appropriate
touchstone because of the processes and issues inherent in
stripping identifying information from electronic medical
records, calls out the unacceptability of having different
deidentification matrixes for research and patient care, and
speculates on the appropriate privacy protective models
with which to supplement deidentification.
In some cases there are relatively obvious solutions to
the issues he exposes. For example, if EMRs currently are
deficient (or inconsistent) in their ability to export deidenti-
fied data, then the current regulatory models being readied
for EMR certification (Office of the National Coordinator for
Health Information Technology) or even the EMR meaning-
ful use matrix (Centers for Medicare & Medicaid Services)
should be harnesses to remedy this deficiency.
Other problem areas (and problematic they are) iden-
tified by Rothstein are not accompanied by any propos-
als. For example, his article offers no approach to the re-
identification issue or solution to the deidentification para-
dox associated with unique data such as genetic informa-
tion derived from biologics. It may be time to reframe these
issues.
Another problem Rothstein identifies is the potential
for group harm. Here he uses the example of the recently
settled litigation between the Havasupai Native Ameri-
can tribe and Arizona State University (Capriccioso 2010).
The solution apparently endorsed by Rothstein is to use
an enhanced informed consent model. Yet it is one that
would be so dependent on speculation by the researcher
that in practice it would be useless, leading to the same
kind of pro forma disclaimers Rothstein criticizes in the
"Commercial Exploitation" section of his article. Consents
to the indeterminate, like waivers of all rights, are insult-
ing to our concept of autonomy and our goal of informed
choice.
Such niggles aside, Rothstein's article forces us to ex-
amine anew some quite fundamental questions, questions
hinted at by some of the opinion data cited in his article.
Lawyers, bioethicists, and regulators (the same ones who
draw the identification binary) have built a decision tree
founded on discrete branches for patients and research sub-
jects. From the perspective of the data steward that may
make sense. But is it meaningful from the perspective of the
patient-subject? Although the research subject likely enters
the endeavor with more sense of altruism toward others
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rather than personal healing, the two roles are unlikely to
be fully dichotomized.
Let us take the Havasupai tribe incident as a container
for this and other questions. Assume the plaintiffs' allega-
tions to be true (the researcher involved has strenuously
denied this; Capriccioso 2010), and that members of the
tribe consented to give blood samples solely to accelerate
research into the tribe's extremely high rate of diabetes. Sup-
pose the research had provided the answer to that and, inci-
dentally, led to a new pharmaceutical to effectively treat di-
abetes, a drug that had immense commercial value. Would
the tribe have objected? Suppose one of the not-consented-
to research areas such as schizophrenia had led to a treat-
ment modality that increased mental health in the tribe.
Physicians and researchers view the consents (treatment,
research, and confidentiality) of their patient-subjects as
a one-time, winner-take-all matter rooted in foresight, not
hindsight; their patients and subjects may not feel so con-
strained.
Recently, one Havasupai tribal council member com-
mented, "I'm not against scientific research ... I just want
it to be done right. They used our blood for all these stud-
ies, people got degrees and grants, and they never asked
our permission" (Harmon 2010). How should lawyers and
bioethicists begin to unpack such a statement? Is this a cry
for our existing consent models? Or for refined ones that
require a far more detailed, sophisticated, and personalized
dialog as required by informed consent? Or do we need to
look elsewhere?
The surveys quoted by Rothstein suggest that tradi-
tional autonomy-based mechanisms such as consent or
waiver (even improved versions of the same) are not
highly regarded by data subjects. Rather, such subjects, in
Rothstein's words, want to "control the use of their samples
and information."
The conclusion to be drawn from this is not that
we need to develop a more nuanced approach to the
identification-deidentification binary accompanied by im-
proved privacy processes. Rather, it suggests we must con-
front a public demand for legal regulation that satisfies their
heightened interests in what comes of the public's EMR data
or biologics (Terry 2010). There are several mechanisms that
would bring increased control. Data or biologics used in re-
search could be limited to those collected from anonymous
sources; a regime of market inalienability (Radin 1987), pro-
hibiting any commercial exploitation of data or biologics,
could be imposed (Terry and Francis 2007); or we could im-
pose some type of "trust" model that would channel profits
or some percentage of profits from research to public funds
or to the research group.
For the research industry (whether profit or nonprofit)
such proposals no doubt are anathematic. But unless such
proposals are put on the table it is hard to believe that we
will have the discussions that we need to find the correct cal-
ibration between researcher and research subject/patient. It
is highly likely that our fellow citizens are far more altru-
istic than we would believe. But until we involve them in
discussion, find the point of accommodation, and regulate
accordingly, we will continue along a tortuous and perhaps
never-ending journey of process reform. *
REFERENCES
Capriccioso, R. 2010. Havasupai blood case settled. Indian Coun-
try Today, April 21. Available at: http://www.indiancountrytoday.
com/archive/91728874.html
Centers for Medicare & Medicaid Services, Medicare and Med-
icaid Programs; Electronic Health Record Incentive Program.
Available at: http://www.ofr.gov/OFRUpload/OFRData/2010-
17207-PI.pdf (accessed July 13, 2010).
Harmon, A. 2010. Indian tribe wins fight to limit research of
its DNA. New York Times, April 21. Available at: http://www.
nytimes.com/2010/04/22/us/22dna.html?scp = 7&sq = havasu-
pai&st = cse
Office of the National Coordinator for Health Information Technol-
ogy, Health Information Technology: Initial Set of Standards, Imple-
mentation Specifications, and Certification Criteria for Electronic
Health Record Technology. Available at: http://www.ofr.gov/
OFRUpload/OFRData/2010-17210-PI.pdf (accessed July 13, 2010).
Radin, M. J. 1987. Market-inalienability. Harvard Law Review 100:
1849-1853.
Rothstein, M. 2010. Is deidentification sufficient to protect health
privacy in research? American Journal of Bioethics 10(9): 3-11.
Terry, N. P. 2010. Legal barriers to realizing the public good in
clinical data. In Institute of Medicine, Clinical data as the basic staple
of health learning: Creating and protecting a public good. Washington,
DC: National Institutes of Health, in press.
Terry, N. P., and L. P. Francis. 2007. Ensuring the privacy and con-
fidentiality of electronic health records. University of Illinois Law
Review 681-735.
September, Volume 10, Number 9, 201032 ajob
